title: [Evaluation of the cardiovascular impact of hormonal replacement therapy in menopausal women].
abstract: Cardiovascular diseases (CVD) are a major cause of female mortality. The occurrence of menopause and estrogen deficiency is a well defined risk factor for CVD. Both retrospective and prospective epidemiological studies indicate that estrogen as well as estrogen-progestin hormone replacement therapy is associated with a reduced incidence of mortality and morbidity due to myocardial infarction or (probably) to stroke by about 50% without any obvious change in venous thromboembolism, when compared to absence of hormone use. A favorable effect of estrogens on the lipid profile could explain about 1/3 of this reduction of risk. Among other potential non-lipid effects of estrogens associated with a positive cardiovascular action, an improvement of insulin secretion together with a decrease in insulin resistance have been noted, this effect being however less obvious if the progestin used has androgenic properties. An improvement of the coagulation-fibrinolysis balance is plausible under treatment, as well as direct action of estrogen on the arterial wall (alteration of both endothelium-dependent and endothelium-independent factors such as a calcium-antagonist effect), leading to an improvement of arterial flow at the coronary, cerebral and peripheral levels. Hormone replacement therapy would be a primary and-potentially-secondary prevention of cardiovascular diseases. However, large prospective, controlled and randomized therapeutic trials that are now underway, are mandatory to definitively establish the cardioprotective effect of hormone replacement therapy.
authors.affiliation: Service de Gynécologie, Centre Hospitalier Universitaire de Liège, Domaine Universitaire du Sart Tilman, Belgique.
authors.forename: U J
authors.initials: UJ
authors.lastname: Gaspard
mesh_terms: D000368:Aged; D002318:Cardiovascular Diseases / Q000453:epidemiology / Q000517:prevention & control*; D015914:Estrogen Replacement Therapy; D005260:Female; D006801:Humans; D008875:Middle Aged; D017698:Postmenopause / Q000187:drug effects*; D011446:Prospective Studies; D012107:Research Design; D012189:Retrospective Studies; D012307:Risk Factors